We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Dramatic Growth Predicted for Global POC Testing Segment

By LabMedica International staff writers
Posted on 19 Oct 2009
The global point-of-care (POC) testing market will experience striking growth from US$12.8 billion in 2008 to $17.8 billion by 2014 according to a new report.

Distributed by Life Science Intelligence (LSI; Huntington Beach, CA, USA), the report provides a global analysis of the patients, procedures, technologies, and companies driving growth and innovation in the POC testing market. More...
It is divided into three main segments: hospital bedside testing products; home and self-testing products; and physician's office lab products.

Each of these areas is divided by product and geography with detailed share-by-supplier information. Various factors contributing to the expected growth include: the demands of physicians for more efficient approaches to the delivery of care; demands for faster access to diagnostic test results to optimize patient outcomes in emergency and critical care settings; the development of advanced analytical technologies, including high-sensitivity assays suitable for POC use, as well as microfluidics technologies that enable highly sophisticated assays to be performed at the bedside by nonlaboratory personnel, with accuracy equivalent to that achieved in the central laboratory; and advanced computer and communications technologies that allow POC testing to be managed as effectively as tests performed in the central lab.

The report is based on a study that included more than 200 interviews with pathologists and laboratory directors; investigators and technical experts; and company presidents, marketing executives, and business development executives.

LSI delivers market data and competitive intelligence to medical technology executives, entrepreneurs, and investors. LSI produces the EMT (Emerging Medical Technologies) Database, EMT (Emerging Medical Technologies) Spotlight events, medtech market reports, and provides global custom research services.

Related Links:

Life Science Intelligence




Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: For decades, laboratories have adjusted total calcium for albumin, but growing evidence shows these corrections often perform poorly and may cause harm (image credit: iStock)

International Experts Recommend Ending Routine 'Corrected' Calcium Reporting

Interpreting serum calcium can be clinically challenging when albumin levels vary, especially in patients with chronic illness or kidney disease. For decades, laboratories have used formulas to adjust... Read more

Molecular Diagnostics

view channel
Image: The integrated multi-omics approach may help identify bladder cancer patients likely to respond to BCG and those needing alternative or intensified treatment (image credit: iStock)

Multi-Omics Profiling Helps Predict BCG Response and Recurrence in Bladder Cancer

High-risk non–muscle-invasive bladder cancer frequently recurs after therapy, with about 30% of patients relapsing and roughly 10% dying within two years despite tumor resection, surveillance, and Bacillus... Read more

Microbiology

view channel
Image: The findings suggest that people with mpox can transmit the virus even without clinical symptoms (image credit: Adobe Stock)

Study Finds Hidden Mpox Infections May Drive Ongoing Spread

Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.